Jia (Jenny) Liu MD PhD
@jiajennyliu.bsky.social
Early Phase Trials Medical Oncologist / Translational Researcher 👩🏻⚕️ @kinghorncancer St Vincent’s Hospital Sydney Associate Professor @UNSW. MOGA Exec. #PrecisionMedicine #drugdevelopment
Passionate about mentorship ❤️ / wellness 🤸🏻♀️/ communication 🧬📣
Passionate about mentorship ❤️ / wellness 🤸🏻♀️/ communication 🧬📣
💡 Dendrimer may offer a non-antibody alternative to improve cytotoxic payload delivery—thanks to EPR effect in tumors
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
August 6, 2025 at 6:01 PM
💡 Dendrimer may offer a non-antibody alternative to improve cytotoxic payload delivery—thanks to EPR effect in tumors
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
Could this be a platform for future payloads?
👏 co-authors @oncocook.bsky.social @anthonymjoshua.bsky.social #Starpharma, #ECMC + #NECTANSW 🇦🇺🇬🇧
🙏 patients, families, site teams
Efficacy:
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
August 6, 2025 at 6:01 PM
Efficacy:
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
DCR: 56.4% (mono 3wkly), 71.4% (mono 2wkly), 81.3% (combo with 5FU)
⏳ mPFS: 2.1, 6.0, 4.2 mo respectively
🔁 Durable benefit:
• PROC: 7 pts ≥6mo (3 >12mo)
• CRC: 12 pts ≥6mo (4 >12mo)
PFS for CRC and ovarian cancer below
Safety:
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
August 6, 2025 at 6:01 PM
Safety:
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
✅ 89.7% of TRAEs were mild/moderate
⚠️ Neutropenia = key DLT + most common grade 3/4 event
❗️Severe GI AEs were rare (G3 diarrhea & vomiting in 0.9%, nausea in 1.8%)
🙅♀️ No cholinergic symptoms observed
📌 Study snapshot:
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
August 6, 2025 at 6:01 PM
📌 Study snapshot:
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
🔬 First-in-human, multi-site (🇦🇺+🇬🇧)
👥 114 patients, Tumors: CRC, ovarian, pancreatic, breast, median 4 prior lines therapy
💉 12.5 mg/m² RP2D mono and combo 5FU
Link to preprint for further details ➡️ arxiv.org/abs/2409.15663
April 25, 2025 at 9:08 PM
Link to preprint for further details ➡️ arxiv.org/abs/2409.15663
Yes it’s amazing app, helpful if you have multiple long haul flights which is frequently my problem working in drug development from 🇦🇺! You get a trial and if you like it worth buying the annual subscription
April 24, 2025 at 5:52 AM
Yes it’s amazing app, helpful if you have multiple long haul flights which is frequently my problem working in drug development from 🇦🇺! You get a trial and if you like it worth buying the annual subscription